Paroxetine updated on 07-01-2025

Hypospadias

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S7470
R22273		 Anderson, 2020 Hypospadias, 2nd or 3rd degree 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.04 [0.50;2.17] -/-   0/- - -
ref
S7350
R21480		 Wemakor, 2015 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among all Antidep (SSRI, SNRI, ...) 1.34 [0.58;3.09] 7/34   3,034/20,090 3,041 34
ref
S18285
R76951		 Reis (Controls exposed to TCA), 2010 Hypospadias early pregnancy population based cohort retrospective exposed to other treatment, sick excluded Adjustment: No Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.38 [0.55;3.48] C
excluded (control group) 		9/1,208   9/1,662 18 1,208
ref
S18286
R76955		 Reis (Controls unexposed, NOS), 2010 Hypospadias early pregnancy population based cohort retrospective unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 2.45 [1.12;4.64] 9/1,208   -/1,062,190 - 1,208
ref
S6160
R16179		 Louik, 2007 Hypospadias 1st trimester case control unexposed (general population or NOS) Adjustment: Yes Monotherapy: substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.00 [0.30;3.30] 3/33   494/6,324 497 33
ref
Total 4 studies 1.46 [0.95;2.24] 3,538 1,275
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Anderson, 2020Anderson, 2020 1.04[0.50; 2.17]--31%ROB confusion: seriousROB selection: criticalROB classification: criticalROB missing: lowROB mesure: unclearROB reporting: moderate Wemakor, 2015Wemakor, 2015 1.34[0.58; 3.09]3,0413424%ROB confusion: criticalROB selection: criticalROB classification: moderateROB missing: lowROB mesure: moderateROB reporting: moderate Reis (Controls unexposed, NOS), 2010Reis, 2010 1 2.45[1.12; 4.64]-1,20833%ROB confusion: criticalROB selection: moderateROB classification: moderateROB missing: lowROB mesure: unclearROB reporting: moderate Louik, 2007Louik, 2007 1.00[0.30; 3.30]4973312%ROB confusion: moderateROB selection: criticalROB classification: criticalROB missing: lowROB mesure: criticalROB reporting: moderate Total (4 studies) I2 = 9% 1.46[0.95; 2.24]3,5381,2750.55.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 2.45[1.20; 4.99]-1,208 -NAReis (Controls unexposed, NOS), 2010 1 case control studiescase control studies 1.13[0.69; 1.87]3,538670%NAAnderson, 2020 Wemakor, 2015 Louik, 2007 3 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.46[0.95; 2.24]3,5381,2759%NAAnderson, 2020 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 4 Tags Adjustment   - Yes  - Yes 1.46[0.95; 2.24]3,5381,2759%NAAnderson, 2020 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 4 Monotherapy   - substance alone among all Antidep ( ...  - substance alone among all Antidep (SSRI, SNRI, ...) 1.16[0.67; 2.02]3,041340%NAAnderson, 2020 Wemakor, 2015 2   - substance alone among the specific ...  - substance alone among the specific class of antidep (SSRI, SNRI, ...) 1.79[0.78; 4.14]4971,24137%NAReis (Controls unexposed, NOS), 2010 Louik, 2007 2 All studiesAll studies 1.46[0.95; 2.24]3,5381,2759%NAAnderson, 2020 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 40.55.01.0

Publication bias and p-hacking diagnosis

funnel plot
0.0-1.41.80.7340.000Anderson, 2020Wemakor, 2015Reis (Controls unexposed, NOS), 2010Louik, 2007

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot
0.01.00.01.0

Sub-groups analysis using all included studies

excluded 18285

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.46[0.95; 2.24]3,5381,2759%NAAnderson, 2020 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 4 exposed to other treatment, sick controlsexposed to other treatment, sick controls 1.38[0.55; 3.48]181,208 -NAReis (Controls exposed to TCA), 2010 10.510.01.0

Umbrella review (other published meta-analyses)

Published MAControlPeriodTE95% CIn exposedkI2 Reefhuis (Hypospadias)Reefhuis (Hypospadias) 1.10[0.60; 1.90]NA-Wwhatever (meta-analysis)Anyduring pregnancy (anytime or not specified)studies TTT4 metaPregmetaPreg 1.46[0.95; 2.24]9%1,275----Anderson, 2020 Wemakor, 2015 Reis (Controls unexposed, NOS), 2010 Louik, 2007 40.510.01.0